JanOne to Host Telebriefing to Discuss Drug Candidate JAN101 for Treatment of Peripheral Artery Disease (PAD) and Potential Applications for COVID-19 Vascular Complications
LAS VEGAS,?Aug. 21, 2020?/PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it intends to provide a public business update via teleconference regarding the advancements made through its lead drug candidate JAN101.? The company believes that JAN101 is a potential treatment for peripheral artery disease (PAD) and may have applications for COVID-19 vascular complications. The briefing will be held on?Tuesday, August 25, 2020?at?4:15 PM ET.
|